《新股消息》德琪醫藥(06996.HK)今起招股 入場費9,131.09元
專注於創新抗腫瘤藥物的亞太地區臨床階段生物製藥公司德琪醫藥(06996.HK)公布招股計劃詳情,計劃發售1.54億股,當中10%為公開發售,另有15%超額配股權。招股價介乎15.8至18.08元,每手500股,入場費9,131.09元。今日(9日)起招股,周四(12日)截止。預期本月20日掛牌上市。聯席保薦人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人為高盛及摩根大通。
公司共獲10名基石投資者認購股份,包括富達、GIC、BlackRock及博裕等,合共1.79億美元(相當於13.9億港元)。
若以中間價16.94元計算,預期集資淨額24.67億元,當中41%將分配予集團的核心產品;25%將用於為集團其他四個臨床階段候選藥物提供資金;9%用於管線中的其他臨床前候選藥物正在進行的臨床前研究及計劃進行的臨床試驗;14%用於擴大其研發管線,包括發現新的候選藥物及業務開發活動;餘下1%及10%分別用於資本開支及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.